Literatur
-
1
Schottmüller H.
Das Problem der Sepsis.
Internist.
1969;
10
93-101
-
2
Bone R C, Balk R A, Cerra F B, Dellinger R P, Fein A M, Knaus W A, Schein R M, Sibbald W J.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.
Chest.
1992;
101
1644-1655
-
3
Dellinger R P, Carlet J M, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall J C, Parker M M, Ramsay G, Zimmerman J L, Vincent J L, Levy M M.
Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Crit Care Med.
2004;
32
858-873
-
4
Vogel F, Bodmann K F.
Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen.
Chemother J.
2004;
13
46-105
-
5
Bochud P Y, Bonten M, Marchetti O, Calandra T.
Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review.
Crit Care Med.
2004;
32 (Suppl)
495-512
-
6
Sandiumenge A, Diaz E, Bodi M, Rello J.
Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of „The Tarragona Strategy”.
Intensive Care Med.
2003;
29
876-83
-
7
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M.
Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med.
2001;
345
1368-1377
-
8
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R.
Intensive insulin therapy in the critically ill patients.
N Engl J Med.
2001;
345
1359-1367
-
9
Annane D, Sebille V, Charpentier C, Bollaert P E, Francois B, Korach J M, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E.
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
JAMA.
2002;
288
862-871
-
10
Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W, Fisher C J Jr.
Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med.
2001;
344
699-709
-
11
Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K.
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
Crit Care Med.
1999;
27
723-732
-
12
Bollaert P E, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A.
Reversal of late septic shock with supraphysiologic doses of hydrocortisone.
Crit Care Med.
1998;
26
645-650
-
13
Vincent J L, Bernard G R, Beale R, Doig C, Putensen C, Dhainaut J F, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin D P, Turlo M A, Janes J. for the ENHANCE Study Group .
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment.
Crit Care Med.
2005;
33
2266-2277
-
14
Abraham E, Laterre P F, Garg R, Levy H, Talwar D, Trzaskoma B L, Francois B, Guy J S, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback B G, Macias W L.
Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
N Engl J Med.
2005;
353
1332-1341
Dr. med. F. Bach
Ltd. OA der Klinik für Anästhesiologie, Intensiv-, Notfallmedizin und Schmerztherapie in Bethel (Campus Gilead) · Evang. Krankenhaus Bielefeld
Burgsteig 13 · 33617 Bielefeld ·
Email: friedhelm.bach@evkb.de
